(via TheNewswire)

Vancouver, British Columbia, November 3, 2026 – TheNewswire - Adaptogenics Health Corp. (“Adaptogenic ” or the “Company ”)(CSE: ADPT ), a company focused on building the future of peptide therapeutics and pharmaceutical-quality supply, is pleased to announce it has engaged InvestorBrandNetwork (“IBN ”), a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.

IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels, and wire services via InvestorWire , along with blogs and other outreach tools, to generate greater awareness for Adaptogenics. With over 20 years of experience assisting over 500 client partners and a sizable family of 75+ trusted brands , IBN has amassed a collective audience that includes millions of social media followers . This positions IBN to provide Adaptogenics the solutions needed to reach a wide audience of investors, journalists, and the general public.

IBN will be compensated US$4,000 per month, for a total of US$48,000 for the initial one-year term, after which the Agreement will continue on a quarter-to-quarter basis unless terminated.There are no performance factors contained in the engagement, and no securities have been or will be provided to IBN or its principals as compensation for the Services. The Company confirms that IBN is an arm’s length service provider and that IBN and its principals do not currently have any direct or indirect interest in the securities of the Company. IBN’s business address is 1108 Lavaca Street, Suite 110, Austin, Texas 78701, and it can be reached at (512) 354-7000 or Editor@IBN.Ai .

About Adaptogenics Health Corp.

Adaptogenics Health Corp. is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.

For more information, investors are encouraged to review the Company’s public filings available at www.sedarplus.ca.

ON BEHALF OF THE BOARD OF DIRECTORS

Gurinder Sandhu, Director

For further information, please contact

Gurinder Sandhu

Director

E: info@adaptogenicscorp.com

Forward-Looking Statements

This news release contains certain statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information, including statements regarding the Company’s business plans, strategies, objectives and expectations. Forward-looking information is generally identified by words such as “may”, “will”, “would”, “could”, “should”, “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “potential” and similar expressions, or the negative thereof. Forward-looking information is based on the reasonable assumptions, estimates and opinions of management as of the date of this news release and is subject to known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking information. For a discussion of the risk factors that may affect the Company, see the Company’s continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca . The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.